Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT). Note: The request metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Filing Type: Form 6-K (Report of Foreign Private Issuer) / ASX Appendix 3B (New Issue Announcement).
Reporting Period: January 2014, with specific transaction dates in early February 2014.
Principal Executive Office: Level 2, 369 Royal Parade, Parkville, Victoria 3052, Australia.
Key Financial Metrics and Capital Structure
Capital Raised: The filing details the issuance of securities for total cash consideration of AUD $896,503.
- Ordinary Shares (Cash): 3,928,900 shares issued for AUD $884,003.
- Ordinary Shares (Cash): 50,000 shares issued for AUD $12,500.
- Unlisted Options (Non-Cash): 300,000 options issued as consideration for a consulting services agreement (100,000 fully vested; 200,000 vesting upon performance milestones).
Share Capital: Total Ordinary Shares quoted on ASX following issuance: 422,659,996.
Options Outstanding: Total unlisted options across various classes: 20,090,218.
Revenue, Profit, and Cash Flow: The filing text does not provide revenue, profit, cash flow, or margin data. This document is a capital issuance announcement, not a financial results report.
Material Changes Versus Prior Period
Share Issuance: The company increased its issued share capital by 3,978,900 ordinary shares and 300,000 unlisted options.
- Ordinary Shares: Issued via the exercise of unlisted options (PBTAI and PBTAW) and pursuant to an employee service agreement dated January 8, 2014.
- Options: New class of 300,000 unlisted options issued with an exercise price of AUD $1.12 and an expiry date of February 5, 2019.
Regulatory Capacity: The company utilized its placement capacity under ASX Listing Rules 7.1 and 7.1A. As of the filing date, remaining placement capacity under Rule 7.1 is 55,466,495 securities, and under Rule 7.1A is 41,576,217 securities.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, earnings outlook, or strategic commentary beyond the mechanics of the share issuance.
Risks and Contingencies: The filing includes standard warranties to the ASX regarding compliance with the Corporations Act and confirms there is no "excluded information" required to be disclosed. No specific operational or financial risks are detailed in this document.
Unusual Items: The issuance of 300,000 options as non-cash consideration for a consulting services agreement is noted as a specific transaction type.
Investor Verification Checklist
- Verify the total number of ordinary shares on issue (422,659,996) against the company's latest ASX announcements to confirm dilution impact.
- Confirm the terms of the "consulting services agreement" referenced for the issuance of 300,000 options to assess the value of non-cash consideration.
- Review the remaining placement capacity (Rule 7.1 and 7.1A) to understand the company's ability to raise further capital without shareholder approval.
- Check the exercise prices and expiry dates of the 20+ million outstanding unlisted options to assess potential future dilution.
- Confirm that the company has not issued any other securities in the 12-month period that were not disclosed in the Annexure 1 calculations.